Rheumatoid Arthritis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Rheumatoid Arthritis Overview

Rheumatoid Arthritis (RA) is an autoimmune disorder of the joints characterized by inflammatory arthritis as well as extra-articular involvement. It commonly involves multiple joints of both hands with morning stiffness that may last for several hours.

“Rheumatoid Arthritis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years. Rheumatoid Arthritis Key players such as – Landos Biopharma, OncoOne, zeta Protein-based vaccine: The University of Toledo, I-Mab Biopharma Co. Ltd., Beijing University of Chinese Medicine, Teijin Pharma, Hemay Pharmaceutical, SynAct Pharma Aps, Alexandria University, R-Pharm, Mabion, GlaxoSmithKline, and others, are developing therapies for the Rheumatoid Arthritis treatment 
• Rheumatoid Arthritis Emerging therapies such as – LABP-69, ON 104, 14-3-3, TJ003234, Guizhi Shaoyao Zhimu Decoction, TCK-276, ABX464: Abivax S.A., Hemay007, AP1189, Trivalent Chromium, Olokizumab, MabionCD20, Otilimab, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.   
• In February 2022, XcimzaneTM, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA®, is a proposed biosimilar that has been developed, manufactured, and commercialised by Biogen Inc. and Xbrane Biopharma AB (certolizumab pegol).
• In May October 2022, Alexandria University initiated a Phase II/III trial to evaluate the efficacy of trivalent chromium supplementation in rheumatoid arthritis treatment and measuring the outcomes of that in rheumatoid arthritis patients
• On 3 June 2020, the Russian Ministry of Health included R-Farm’s new drug, Artlegia (olokizumab), to its COVID-19 Prevention, Diagnosis, and Treatment Provisional Guidelines. Artlegia is the first Russian original drug included to the guidelines of the Russian Ministry of Health.

Route of Administration

Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Rheumatoid Arthritis Pipeline Therapeutics Assessment

• Rheumatoid Arthritis Assessment by Product Type
• Rheumatoid Arthritis By Stage and Product Type
• Rheumatoid Arthritis Assessment by Route of Administration
• Rheumatoid Arthritis By Stage and Route of Administration
• Rheumatoid Arthritis Assessment by Molecule Type
• Rheumatoid Arthritis by Stage and Molecule Type

DelveInsight’s Rheumatoid Arthritis Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:

Key companies developing therapies for Rheumatoid Arthritis are – Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others.

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:

• LABP-69: Landos Biopharma
• ON 104: OncoOne
• 14-3-3 zeta Protein-based vaccine: The University of Toledo
• TJ003234: I-Mab Biopharma Co. Ltd.
• Guizhi Shaoyao Zhimu Decoction: Beijing University of Chinese Medicine
• TCK-276: Teijin Pharma
• ABX464: Abivax S.A.
• Hemay007: Hemay Pharmaceutical
• AP1189: SynAct Pharma Aps
• Trivalent Chromium: Alexandria University
• Olokizumab: R-Pharm
• MabionCD20: Mabion
• Otilimab: GlaxoSmithKline

Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

Rheumatoid Arthritis Pipeline Analysis:

The Rheumatoid Arthritis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
• Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies

Rheumatoid Arthritis Pipeline Market Drivers

• Rising prevalence of arthritis worldwide
• Acceptance of biosimilars for treatment of Rheumatoid Arthritis

Rheumatoid Arthritis Pipeline Market Barriers

• High cost of biologics
• Lack of resources in underdeveloped nations

Scope of Rheumatoid Arthritis Pipeline Drug Insight    

• Coverage: Global
• Key Rheumatoid Arthritis Companies: Landos Biopharma, OncoOne, zeta Protein-based vaccine: The University of Toledo, I-Mab Biopharma Co. Ltd., Beijing University of Chinese Medicine, Teijin Pharma, Hemay Pharmaceutical, SynAct Pharma Aps, Alexandria University, R-Pharm, Mabion, GlaxoSmithKline, and others
• Key Rheumatoid Arthritis Therapies: LABP-69, ON 104, 14-3-3, TJ003234, Guizhi Shaoyao Zhimu Decoction, TCK-276, ABX464: Abivax S.A., Hemay007, AP1189, Trivalent Chromium, Olokizumab, MabionCD20, Otilimab, and others
• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers 

Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis